News Pfizer targets $2.5bn more in cost savings Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.
News BMS, Pfizer take DTC route for blood thinner Eliquis BMS, Pfizer launch direct-to-patient sales for anticoagulant Eliquis, as a report cites conflict-of-interest concerns about the emerging DTC channel.
News BMS files legal challenge to HHS' 340B rebate decision Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.
News Pfizer's COVID boom goes on, as it eyes $22bn in Paxlovid sa... Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirna
News BMS shakes up R&D under CMO Cristian Massacesi Bristol Myers Squibb is combining its R&D operations into a single unit led by chief medical officer and development head Cristian Massacesi.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
